text: COVID 19 potential therapeutics for pediatric patients The global spread of COVID 19 has imparted significant economic medical and social burdens Like adults children are affected by this pandemic However milder clinical symptoms are often experienced by them Only a minimal proportion of the affected patients may develop severe and complicated COVID 19 Supportive treatment is recommended in all patients Antiviral and immunomodulatory medications are spared for hospitalized children with respiratory distress or severe to critical disease Up till now remdesivir is the only USFDA approved anti COVID 19 medication indicated in the majority of symptomatic patients with moderate to severe disease Dexamethasone is solely recommended in patients with respiratory distress maintained on oxygen or ventilatory support The use of these medications in pediatric patients is founded on evidence deriving from adult studies No randomized controlled trials RCTs involving pediatric COVID 19 patients have assessed these medications efficacy and safety among others Similarly three novel monoclonal anti SARS CoV 2 spike protein antibodies bamlanivimab casirivimab and imdevimab have been recently authorized by the USFDA Nonetheless their efficacy has not been demonstrated by multiple RCTs In this review we aim to dissect the various potential therapeutics used in children with COVID 19 We aspire to provide a comprehensive review of the available evidence and display the mechanisms of action and the pharmacokinetic properties of the studied therapeutics Our review offers an efficient and practical guide for treating children with COVID 19 